Latest News

AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment

VANCOUVER, British Columbia–(BUSINESS WIRE)– #AbCellera–LY-CoV555, the lead antibody from the AbCellera and Lilly collaboration, has entered into human testing for the potential treatment of COVID-19.

Source link

Related posts

New technology can improve sound quality for hearing implant users


Rydberg-State-Resolved Resonant Energy Transfer in Cold Electric-Field-Controlled Intrabeam Collisions of NH3 with Rydberg He Atoms


Samenvatting: Axonics® kondigt goedkeuring van Amerikaanse voedsel- en medicijnadministratie aan voor sacraal neuromodulatiesysteem voor urinaire klinische indicaties


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World